Clinical Trials Directory

Trials / Unknown

UnknownNCT04088513

Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

A Randomized, Double-blind, Active-Controlled Trial Comparing the Safety and Efficacy of Aspirin Versus Clopidogrel in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
440 (estimated)
Sponsor
First Affiliated Hospital, Sun Yat-Sen University · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency on some occasions, while still widely uesd for stroke prevention. The SAST trial is designed to evaluate the safety and efficacy of aspirin in patients this enzyme disorder.The primary purpose of the trial is to evaluate the hemolytic effects of a 3-month regimen of aspirin 100mg/d versus a 3-month regimen of clopidogrel 75mg/d.

Detailed description

This SAST trial is a prospective, multicenter, randomized, double-blind trial.440 acute ischemic stroke (AIS) patients with G6PD deficiency will be randomized to receive a 3-month regimen of aspirin 100mg/d or clopidogrel 75mg/d. The primary end point is the proportion of protocol-defined hemolysis at 90 days. Protocol-defined hemolysis is defined as one or more of the following conditions: a) Hemoglobin level declined ≥2.5 g/dL from baseline, meanwhile ruling out bleeding events. b) Hemoglobin level declined ≥25% from baseline, meanwhile ruling out bleeding events. c) Clinically relevant hemolytic events, could manifested as fatigue, back pain, anemia, dark urine and jaundice. The study consists of five visits including the day of randomization, day 4, day10±3days, day27±3days, day90±7days.

Conditions

Interventions

TypeNameDescription
DRUGAspirinThis group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
DRUGClopidogrelThis group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.

Timeline

Start date
2020-01-22
Primary completion
2024-12-31
Completion
2024-12-31
First posted
2019-09-12
Last updated
2022-03-16

Locations

19 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04088513. Inclusion in this directory is not an endorsement.